Journal: International Journal of Nanomedicine

Article Title: Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy

doi: 10.2147/IJN.S606369

Figure Lengend Snippet: In vitro antitumor efficacy and hemocompatibility evaluation. ( a ) Cytotoxicity of free THAM, free CLB, a CLB/THAM physical mixture, and CLB-THAM nanomicelles against A20 cells after 24 h of incubation, as determined by the CCK-8 assay. Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001. ( b ) Photograph of the hemolysis assay after co-incubation of erythrocytes with different formulations. And Hemolysis rates of the CLB-THAM nanomicelles at different concentrations. Pure water and 0.9% NaCl solution were used as positive and negative controls, respectively. Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001.

Article Snippet: The A20 cell line used in this study was purchased from Wuhan Zishan Biotechnology Co., Ltd. (originally sourced from ATCC, TIB-208).

Techniques: In Vitro, Incubation, CCK-8 Assay, Standard Deviation, Hemolysis Assay

Journal: International Journal of Nanomedicine

Article Title: Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy

doi: 10.2147/IJN.S606369

Figure Lengend Snippet: Flow cytometric analysis of apoptosis in A20 cells induced by free CLB and CLB-THAM nanomicelles. Cells were treated with various concentrations (5, 15, and 30 μg·mL −1 , CLB-equivalent) for 24 h, and apoptosis was assessed by Annexin V-FITC/PI staining.

Article Snippet: The A20 cell line used in this study was purchased from Wuhan Zishan Biotechnology Co., Ltd. (originally sourced from ATCC, TIB-208).

Techniques: Staining

Journal: International Journal of Nanomedicine

Article Title: Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy

doi: 10.2147/IJN.S606369

Figure Lengend Snippet: Comparative analysis of the cellular uptake and localization of free DID and DID@CLB-THAM nanomicelles in A20 cells over time. CLSM images after 2 h, 4 h, and 8 h of incubation reveal differences in uptake pathways and distribution patterns between the two formulations. Scale bar: 50 μm.

Article Snippet: The A20 cell line used in this study was purchased from Wuhan Zishan Biotechnology Co., Ltd. (originally sourced from ATCC, TIB-208).

Techniques: Incubation

Journal: International Journal of Nanomedicine

Article Title: Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy

doi: 10.2147/IJN.S606369

Figure Lengend Snippet: In vivo antitumor efficacy and safety evaluation of CLB-THAM nanomicelles in A20 tumor-bearing mice. ( a ) Body weight changes of mice during the 15-day treatment period, Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001. ( b ) Tumor growth curves showing tumor volume as a function of time after administration of saline, free CLB, or CLB-THAM nanomicelles, Data are presented as mean ± standard deviation (SD), (n = 5), * means P < 0.05, *** means P < 0.001. ( c ) Final tumor weights measured on day 15, Data are presented as mean ± standard deviation (SD), n = 5, *** means P < 0.001. ( d ) Representative photographs of excised tumors from each treatment group at the end of the experiment. ( e ) Histopathological analysis of major organs (heart, liver, spleen, lung, kidney) and tumor tissues by H&E staining. Scale bar: 50 μm. ( f ) Apoptosis in tumor tissues detected by TUNEL staining. Scale bar: 25 μm.

Article Snippet: The A20 cell line used in this study was purchased from Wuhan Zishan Biotechnology Co., Ltd. (originally sourced from ATCC, TIB-208).

Techniques: In Vivo, Standard Deviation, Saline, Staining, TUNEL Assay

Journal: Cancers

Article Title: Myeloid Cell-Targeting PLGA Nanoparticles Ameliorate Acute Graft-Versus-Host Disease

doi: 10.3390/cancers18091431

Figure Lengend Snippet: IMPs prevent GVHD while maintaining a GVT effect. Lethally irradiated (950 Gy) BALB/c mice were infused with B6 BM cells (±splenocytes and ±PLGA-IMPs) as previously described. Mice were also intravenously injected on the day of transplant with 2 × 10 6 A20 lymphoma cell line expressing luciferase (A20-luc). The top figure is a representative image from in vivo bioimaging of A20-luc treated mice. Color represents tumor location and density. Kaplan–Meier survival curve from three separate experiments (Mantle-Cox test).

Article Snippet: The A20 lymphoma cells are a BALB/c B-cell lymphoma line derived from a spontaneous reticulum cell neoplasm (ATCC, catalog number: TIB-208, Manassas, VA, USA) and were infected with a lentiviral vector that co-expresses firefly luciferase (Luc) and an enhanced green fluorescent protein (EGFP) to create A20-luc cells.

Techniques: Irradiation, Injection, Expressing, Luciferase, In Vivo

Journal: bioRxiv

Article Title: Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency

doi: 10.64898/2026.03.18.712771

Figure Lengend Snippet: A20-HE2.1 or uninfected (parental) A20 cells were treated with vehicle (water or DMSO), Palbociclib (Palbo), or Dinaciclib (Dina) concurrent with PMA+NaB for 24 hours. Cell viability was quantified by trypan blue staining or flow cytometry using LIVE/DEAD-Near IR stain. Viability was normalized to vehicle-treated condition for control or PMA+NaB. Mean relative viability +/-SEM based on trypan blue staining shown for A20-HE2.1 (A) or parental A20 (B) cells. Mean relative viability +/- SEM based on LIVE-DEAD-Near IR staining (C) , with representative flow cytometry plots showing percentage of cells that are live (yellow) (D) . (*p<0.05; A: n=8 for Palbo, n=6 for Dina; B: n=2; C: n=3)

Article Snippet: Parental A20 B cells (ATCC TIB208) were cultured in RPMI 1640 (Gibco) supplemented with 10% bovine serum (FBS, Atlanta Biologicals) and 50 μM 2-mercaptoethanol (VWR).

Techniques: Staining, Flow Cytometry, Control

Journal: Cell Reports Medicine

Article Title: Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy

doi: 10.1016/j.xcrm.2026.102632

Figure Lengend Snippet: Val-ILs affect immunosuppressive cells and B lymphoma growth BALB/c mice were s.c. injected with 10 6 A20 cells. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) on days 6, 9, and 12. Analyses were performed on day 15. (A) UMAP data frame and heatmap following FC showing the expression levels of the nine antigens targeted by Val-ILs-Combo among immune cells detected in the TME. Mean normalized data of n = 8 untreated mice. (B) NPs reduced the tumor volumes measured in vivo. Image of tumors isolated ex vivo , n = 8 mice per group, four did not develop tumors (black cross). (C) UMAP data showing that Val-ILs-Combo affected the repartition of immune cells in the TME. (D) NPs affected the repartition of immune cells in the spleen. (E and F) Val-ILs-Combo reduced the amount of Th17, Tregs, MDSCs, TAMs, or macrophages, in the TME (E) and the spleen (F). (G) Histogram showing the number of antigens targeted by the NPs and found repressed on the cell surface of various immune cell populations. (H) FC on TAMs in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (I) FC on tDCs in the TME and DCs in the spleen, to identify the percentage of activated MHC II + DCs. (J) FC on CD4 + and CD8 + T-Ly in the TDLNs showing an increase in these populations. (K) FC showing that Val-ILs-Combo reduced the amount of Th17 and Tregs in the TDLNs. (L) Tumor growth volumes measured in vivo following the injection of Val-ILs-Combo and/or αPD-1 (200 μg). Image of tumors isolated ex vivo , n = 8 mice per group. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG and are calculated using a two-tailed unpaired Student’s t test. See also .

Article Snippet: In this study, we utilized the murine T lymphoma EL4 cells (ATCC, TIB-39, C57BL/6 strain), the murine B lymphoma A20 cells (ATCC, TIB-208, BALB/c strain), the murine breast cancer 4T1 cells (ATCC, CRL-2539, BALB/c strain) and the murine Lewis lung carcinoma LLC1 (LL/2) cells (ATCC, CRL-1642, C57BL/6 strain).

Techniques: Injection, Expressing, In Vivo, Isolation, Ex Vivo, Two Tailed Test